Who are Gemcitabine plus Capecitabine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gemcitabine-plus-capecitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Gemcitabine plus Capecitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gemcitabine plus Capecitabine (Gemcitabine plus Capecitabine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog and thymidylate synthase inhibitor. Area: Oncology.

phase 2 Nucleoside analog and thymidylate synthase inhibitor DNA polymerase and thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Gemcitabine plus Capecitabine (Gemcitabine plus Capecitabine) — Asan Medical Center. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while Capecitabine is a prodrug of 5-fluorouracil that inhibits thymidylate synthase.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gemcitabine plus Capecitabine TARGET	Gemcitabine plus Capecitabine	Asan Medical Center	phase 2	Nucleoside analog and thymidylate synthase inhibitor	DNA polymerase and thymidylate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog and thymidylate synthase inhibitor class)

Asan Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gemcitabine plus Capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/gemcitabine-plus-capecitabine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab